The antibiotic effects of vitamin D

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 14, Issue 4, 2014, Pages 255-266

  Guo, Chunxiao ^a   Gombart, Adrian F ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial peptide; Cathelicidin; Infection; Innate immunity; Vitamin D; Vitamin D receptor

Indexed keywords

CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; FORMYLPEPTIDE RECEPTOR; PURINERGIC P2X7 RECEPTOR; TOLL LIKE RECEPTOR; VITAMIN D; 25-HYDROXYVITAMIN D; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CATHELICIDIN ANTIMICROBIAL PEPTIDE GENE; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INNATE IMMUNITY; LUNG TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TISSUE INJURY; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BIOFILM; BLOOD; DRUG EFFECTS; GENETICS; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; HUMANS; TOLL-LIKE RECEPTORS; VITAMIN D;

EID: 84924295616     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530314666140709085159     Document Type: Article

References (162)

1. Levine, E.B. (1971) Hippocrates, Twayne Publishers, New York.
2. Koch, R. (1901) An address on the fight against tuberculosis in the light of the experience that has been gained in the successful combat of other infectious diseases. Br. Med. J., 2, 189-193.
3. Howson, C.R. (1928) Heliotherapy in pulmonary tuberculosis-its possibilities and dangers. Cal. West Med., 29, 25-30.
4. Gotzsche, P.C. Niels finsen's treatment for lupus vulgaris. J. R. Soc. Med., 104, 41-42.
5. Norman, A.W. The history of the discovery of vitamin d and its daughter steroid hormone. Ann. Nutr. Metab., 61, 199-206.
6. Bikle, D. (2009) Nonclassic actions of vitamin d. J. Clin. Endocrinol. Metab., 94, 26-34.
7. Holick, M.F., and Chen, T.C. (2008) Vitamin d deficiency: A worldwide problem with health consequences. Am. J. Clin. Nutr., 87, 1080S-1086S.
8. Dowling, G.B. (1946) New remedy for lupus. Lancet, 1, 590.
9. Gaumond, E. (1948) Lupus vulgaris and vitamin d. Can. Med. Assoc. J., 59, 522-527.
10. Jones, D.; Metzger, H.J.; Schatz, A. and Waksman, S.A. (1944) Control of gram-negative bacteria in experimental animals by streptomycin. Science, 100, 103-105.
11. Herrell, W.E. and Nichols, D.R. (1945) The clinical use of streptomycin. Proc. Staff Meet Mayo Clin., 20, 449-462.
12. Davies, P.D. (1985) A possible link between vitamin d deficiency and impaired host defence to mycobacterium tuberculosis. Tubercle, 66, 301-306.
13. Haug, C.; Muller, F.; Aukrust, P. and Froland, S.S. (1994) Subnormal serum concentration of 1, 25-vitamin d in human immunodeficiency virus infection: Correlation with degree of immune deficiency and survival. J. Infect. Dis., 169, 889-893.
14. Wilkinson, R.J.; Llewelyn, M.; Toossi, Z.; Patel, P.; Pasvol, G.; Lalvani, A.; Wright, D.; Latif, M. and Davidson, R.N. (2000) Influence of vitamin d deficiency and vitamin d receptor polymorphisms on tuberculosis among gujarati asians in west london: A case-control study. Lancet, 355, 618-621.
15. Rook, G.A.; Steele, J.; Fraher, L.; Barker, S.; Karmali, R.; O'Riordan, J. and Stanford, J. (1986) Vitamin d3, gamma interferon, and control of proliferation of mycobacterium tuberculosis by human monocytes. Immunology, 57, 159-163.
16. Rockett, K.A.; Brookes, R.; Udalova, I.; Vidal, V.; Hill, A.V. and Kwiatkowski, D. (1998) 1, 25-dihydroxyvitamin d3 induces nitric oxide synthase and suppresses growth of mycobacterium tuberculosis in a human macrophage-like cell line. Infect. Immun., 66, 5314-5321.
17. Sly, L.M.; Lopez, M.; Nauseef, W.M. and Reiner, N.E. (2001) 1alpha, 25-dihydroxyvitamin d3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the nadph-dependent phagocyte oxidase. J. Biol. Chem., 276, 35482-35493.
18. Denis, M. (1994) Human monocytes/macrophages: No or no no? J. Leukoc. Biol., 55, 682-684.
19. Fazal, N. (1997) The role of reactive oxygen species (ros) in the effector mechanisms of human antimycobacterial immunity. Biochem. Mol. Biol. Int., 43, 399-408.
20. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S. and White, J.H. (2004) Cutting edge: 1, 25-dihydroxyvitamin d3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol., 173, 2909-2912.
21. Weber, G.; Heilborn, J.D.; Chamorro Jimenez, C.I.; Hammarsjo, A.; Torma, H. and Stahle, M. (2005) Vitamin d induces the antimicrobial protein hcap18 in human skin. J. Invest. Dermatol., 124, 1080-1082.
22. Gombart, A.F.; Borregaard, N. and Koeffler, H.P. (2005) Human cathelicidin antimicrobial peptide (camp) gene is a direct target of the vitamin d receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin d3. FASEB J., 19, 1067-1077.
23. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.; Meinken, C.; Kamen, D.L.; Wagner, M.; Bals, R.; Steinmeyer, A.; Zugel, U.; Gallo, R.L.; Eisenberg, D.; Hewison, M.; Hollis, B.W.; Adams, J.S.; Bloom, B.R. and Modlin, R.L. (2006) Toll-like receptor triggering of a vitamin d-mediated human antimicrobial response. Science, 311, 1770-1773.
24. Liu, P.T.; Stenger, S.; Tang, D.H. and Modlin, R.L. (2007) Cutting edge: Vitamin d-mediated human antimicrobial activity against mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol., 179, 2060-2063.
25. Yuk, J.M.; Shin, D.M.; Lee, H.M.; Yang, C.S.; Jin, H.S.; Kim, K.K.; Lee, Z.W.; Lee, S.H.; Kim, J.M., and Jo, E.K. (2009) Vitamin d3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe, 6, 231-243.
26. Shin, D.M.; Yuk, J.M.; Lee, H.M.; Lee, S.H.; Son, J.W.; Harding, C.V.; Kim, J.M.; Modlin, R.L. and Jo, E.K. (2010) Mycobacterial lipoprotein activates autophagy via tlr2/1/cd14 and a functional vitamin d receptor signalling. Cell Microbiol., 12, 1648-1665.
27. Fabri, M.; Stenger, S.; Shin, D.M.; Yuk, J.M.; Liu, P.T.; Realegeno, S.; Lee, H.M.; Krutzik, S.R.; Schenk, M.; Sieling, P.A.; Teles, R.; Montoya, D.; Iyer, S.S.; Bruns, H.; Lewinsohn, D.M.; Hollis, B.W.; Hewison, M.; Adams, J.S.; Steinmeyer, A.; Zugel, U.; Cheng, G.; Jo, E.K.; Bloom, B.R. and Modlin, R.L. Vitamin d is required for ifn-gamma-mediated antimicrobial activity of human macrophages. Sci. Transl. Med., 3, 104ra102.
28. Teles, R.M.; Graeber, T.G.; Krutzik, S.R.; Montoya, D.; Schenk, M.; Lee, D.J.; Komisopoulou, E.; Kelly-Scumpia, K.; Chun, R.; Iyer, S.S.; Sarno, E.N.; Rea, T.H.; Hewison, M.; Adams, J.S.; Popper, S.J.; Relman, D.A.; Stenger, S.; Bloom, B.R.; Cheng, G. and Modlin, R.L. Type i interferon suppresses type ii interferontriggered human anti-mycobacterial responses. Science, 339, 1448- 1453.
29. Bacchetta, J.; Zaritsky, J.J.; Sea, J.L.; Chun, R.F.; Lisse, T.S.; Zavala, K.; Nayak, A.; Wesseling-Perry, K.; Westerman, M.; Hollis, B.W.; Salusky, I.B. and Hewison, M. (2014) Suppression of iron-regulatory hepcidin by vitamin d. J. Am. Soc. Nephrol., 25, 564-572.
30. Sita-Lumsden, A.; Lapthorn, G.; Swaminathan, R. and Milburn, H.J. (2007) Reactivation of tuberculosis and vitamin d deficiency: The contribution of diet and exposure to sunlight. Thorax, 62, 1003-1007.
31. Wejse, C.; Olesen, R.; Rabna, P.; Kaestel, P.; Gustafson, P.; Aaby, P.; Andersen, P.L.; Glerup, H. and Sodemann, M. (2007) Serum 25-hydroxyvitamin d in a west african population of tuberculosis patients and unmatched healthy controls. Am. J. Clin. Nutr., 86, 1376-1383.
32. Gibney, K.B.; MacGregor, L.; Leder, K.; Torresi, J.; Marshall, C.; Ebeling, P.R. and Biggs, B.A. (2008) Vitamin d deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-saharan africa. Clin. Infect. Dis., 46, 443-446.
33. Perez-Trallero, E.; Cilla, G.; Garcia-Zamalloa, A. and Idigoras, P. (2008) Vitamin d and tuberculosis incidence in spain. Am. J. Respir. Crit. Care. Med., 177, 798-799; author reply 799.
34. Williams, B.; Williams, A.J. and Anderson, S.T. (2008) Vitamin d deficiency and insufficiency in children with tuberculosis. Pediatr. Infect. Dis. J., 27, 941-942.
35. Friis, H.; Range, N.; Changalucha, J.; Praygod, G.; Jeremiah, K.; Faurholt-Jepsen, D.; Krarup, H.; Molgaard, C. and Andersen, A. Vitamin d status among pulmonary tb patients and non-tb controls: A cross-sectional study from mwanza, tanzania. PLoS ONE, 8, e81142.
36. Selvaraj, P.; Prabhu Anand, S.; Harishankar, M. and Alagarasu, K. (2009) Plasma 1, 25 dihydroxy vitamin d3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. J. Clin. Immunol., 29, 470-478.
37. Yamshchikov, A.V.; Kurbatova, E.V.; Kumari, M.; Blumberg, H.M.; Ziegler, T.R.; Ray, S.M. and Tangpricha, V. (2010) Vitamin d status and antimicrobial peptide cathelicidin (ll-37) concentrations in patients with active pulmonary tuberculosis. Am. J. Clin. Nutr., 92, 603-611.
38. Ho-Pham, L.T.; Nguyen, N.D.; Nguyen, T.T.; Nguyen, D.H.; Bui, P.K.; Nguyen, V.N. and Nguyen, T.V. Association between vitamin d insufficiency and tuberculosis in a vietnamese population. BMC Infect. Dis., 10, 306.
39. Arya, S.C. and Agarwal, N. Vitamin d deficiency in adult tuberculosis patients. Int. J. Tuberc. Lung Dis., 15, 1133-1134.
40. Martineau, A.R.; Wilkinson, K.A.; Newton, S.M.; Floto, R.A.; Norman, A.W.; Skolimowska, K.; Davidson, R.N.; Sorensen, O.E.; Kampmann, B.; Griffiths, C.J. and Wilkinson, R.J. (2007) Ifngamma- and tnf-independent vitamin d-inducible human suppression of mycobacteria: The role of cathelicidin ll-37. J. Immunol., 178, 7190-7198.
41. Nursyam, E.W.; Amin, Z. and Rumende, C.M. (2006) The effect of vitamin d as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta. Med. Indones., 38, 3-5.
42. Morcos, M.M.; Gabr, A.A.; Samuel, S.; Kamel, M.; el Baz, M.; el Beshry, M. and Michail, R.R. (1998) Vitamin d administration to tuberculous children and its value. Boll. Chim. Farm., 137, 157- 164.
43. Wejse, C.; Gomes, V.F.; Rabna, P.; Gustafson, P.; Aaby, P.; Lisse, I.M.; Andersen, P.L.; Glerup, H. and Sodemann, M. (2009) Vitamin d as supplementary treatment for tuberculosis: A doubleblind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med., 179, 843-850.
44. Martineau, A.R.; Timms, P.M.; Bothamley, G.H.; Hanifa, Y.; Islam, K.; Claxton, A.P.; Packe, G.E.; Moore-Gillon, J.C.; Darmalingam, M.; Davidson, R.N.; Milburn, H.J.; Baker, L.V.; Barker, R.D.; Woodward, N.J.; Venton, T.R.; Barnes, K.E.; Mullett, C.J.; Coussens, A.K.; Rutterford, C.M.; Mein, C.A.; Davies, G.R.; Wilkinson, R.J.; Nikolayevskyy, V.; Drobniewski, F.A.; Eldridge, S.M. and Griffiths, C.J. (2011) High-dose vitamin d(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. Lancet, 377, 242-250.
45. Coussens, A.K.; Wilkinson, R.J.; Hanifa, Y.; Nikolayevskyy, V.; Elkington, P.T.; Islam, K.; Timms, P.M.; Venton, T.R.; Bothamley, G.H.; Packe, G.E.; Darmalingam, M.; Davidson, R.N.; Milburn, H.J.; Baker, L.V.; Barker, R.D.; Mein, C.A.; Bhaw-Rosun, L.; Nuamah, R.; Young, D.B.; Drobniewski, F.A.; Griffiths, C.J. and Martineau, A.R. Vitamin d accelerates resolution of inflammatory responses during tuberculosis treatment. Proc. Natl. Acad. Sci. USA., 109, 15449-15454.
46. Salahuddin, N.; Ali, F.; Hasan, Z.; Rao, N.; Aqeel, M., and Mahmood, F. Vitamin d accelerates clinical recovery from tuberculosis: Results of the succinct study [supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin d supplementation in patients with pulmonary tuberculosis'. BMC Infect. Dis., 13, 22.
47. Bodnar, L.M.; Krohn, M.A. and Simhan, H.N. (2009) Maternal vitamin d deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J. Nutr., 139, 1157-1161.
48. Villamor, E. (2006) A potential role for vitamin D on HIV infection? Nutr. Rev., 64, 226-233.
49. Reinton, N.; Haugen, T.B.; Orstavik, S.; Skalhegg, B.S.; Hansson, V.; Jahnsen, T. and Tasken, K. (1998) The gene encoding the c gamma catalytic subunit of camp-dependent protein kinase is a transcribed retroposon. Genomics, 49, 290-297.
50. Aloia, J.F. and Li-Ng, M. (2007) Re: Epidemic influenza and vitamin d. Epidemiol. Infect., 135, 1095-1096; author reply 1097- 1098.
51. Urashima, M.; Segawa, T.; Okazaki, M.; Kurihara, M.; Wada, Y. and Ida, H. (2010) Randomized trial of vitamin d supplementation to prevent seasonal influenza a in schoolchildren. Am. J. Clin. Nutr., 91, 1255-1260.
52. Avenell, A.; Cook, J.A.; Maclennan, G.S. and Macpherson, G.C. (2007) Vitamin d supplementation to prevent infections: A substudy of a randomised placebo-controlled trial in older people (record trial, isrctn 51647438). Age Ageing, 36, 574-577.
53. Grant, W.B. and Holick, M.F. (2005) Benefits and requirements of vitamin d for optimal health: A review. Altern. Med. Rev., 10, 94- 111.
54. Aloia, J.F.; Talwar, S.A.; Pollack, S. and Yeh, J. (2005) A randomized controlled trial of vitamin d3 supplementation in african american women. Arch. Intern. Med., 165, 1618-1623.
55. Sabetta, J.R.; DePetrillo, P.; Cipriani, R.J.; Smardin, J.; Burns, L.A. and Landry, M.L. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS ONE, 5, e11088.
56. Bergman, P.; Norlin, A.C.; Hansen, S.; Rekha, R.S.; Agerberth, B.; Bjorkhem-Bergman, L.; Ekstrom, L.; Lindh, J.D. and Andersson, J. Vitamin d3 supplementation in patients with frequent respiratory tract infections: A randomised and double-blind intervention study. BMJ Open, 2, e001663.
57. Li-Ng, M.; Aloia, J.F.; Pollack, S.; Cunha, B.A.; Mikhail, M.; Yeh, J. and Berbari, N. (2009) A randomized controlled trial of vitamin d3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol. Infect., 137, 1396-1404.
58. Roth, D.E.; Jones, A.B.; Prosser, C.; Robinson, J.L. and Vohra, S. (2009) Vitamin d status is not associated with the risk of hospitalization for acute bronchiolitis in early childhood. Eur. J. Clin. Nutr., 63, 297-299.
59. Larrick, J.W.; Morgan, J.G.; Palings, I.; Hirata, M. and Yen, M.H. (1991) Complementary DNA sequence of rabbit cap18--a unique lipopolysaccharide binding protein. Biochem. Biophys. Res. Commun., 179, 170-175.
60. Larrick, J.W.; Hirata, M.; Shimomoura, Y.; Yoshida, M.; Zheng, H.; Zhong, J. and Wright, S.C. (1993) Antimicrobial activity of rabbit cap18-derived peptides. Antimicrob. Agents Chemother., 37, 2534-2539.
61. Larrick, J.W.; Hirata, M.; Shimomoura, Y.; Yoshida, M.; Zheng, H.; Zhong, J. and Wright, S.C. (1994) Rabbit cap18 derived peptides inhibit gram negative and gram positive bacteria. Prog. Clin. Biol. Res., 388, 125-135.
62. Larrick, J.W.; Hirata, M.; Balint, R.F.; Lee, J.; Zhong, J. and Wright, S.C. (1995) Human cap18: A novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun., 63, 1291-1297.
63. Cowland, J.B.; Johnsen, A.H. and Borregaard, N. (1995) Hcap-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett., 368, 173-176.
64. Larrick, J.W.; Hirata, M.; Zhong, J. and Wright, S.C. (1995) Antimicrobial activity of human cap18 peptides. Immunotechnology, 1, 65-72.
65. Zanetti, M.; Gennaro, R. and Romeo, D. (1995) Cathelicidins: A novel protein family with a common proregion and a variable cterminal antimicrobial domain. FEBS Lett., 374, 1-5.
66. Turner, J.; Cho, Y.; Dinh, N.N.; Waring, A.J. and Lehrer, R.I. (1998) Activities of ll-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother., 42, 2206-2214.
67. Saiman, L.; Tabibi, S.; Starner, T.D.; San Gabriel, P.; Winokur, P.L.; Jia, H.P.; McCray, P.B., Jr. and Tack, B.F. (2001) Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob. Agents Chemother., 45, 2838-2844.
68. Oren, Z.; Lerman, J.C.; Gudmundsson, G.H.; Agerberth, B. and Shai, Y. (1999) Structure and organization of the human antimicrobial peptide ll-37 in phospholipid membranes: Relevance to the molecular basis for its non-cell-selective activity. Biochem. J., 341 (Pt 3), 501-513.
69. Overhage, J.; Campisano, A.; Bains, M.; Torfs, E.C.; Rehm, B.H. and Hancock, R.E. (2008) Human host defense peptide ll-37 prevents bacterial biofilm formation. Infect. Immun., 76, 4176- 4182.
70. Chennupati, S.K.; Chiu, A.G.; Tamashiro, E.; Banks, C.A.; Cohen, M.B.; Bleier, B.S.; Kofonow, J.M.; Tam, E. and Cohen, N.A. (2009) Effects of an ll-37-derived antimicrobial peptide in an animal model of biofilm pseudomonas sinusitis. Am. J. Rhinol. Allergy, 23, 46-51.
71. Amer, L.S.; Bishop, B.M. and van Hoek, M.L. (2010) Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against francisella. Biochem. Biophys. Res. Commun., 396, 246-251.
72. Kai-Larsen, Y.; Luthje, P.; Chromek, M.; Peters, V.; Wang, X.; Holm, A.; Kadas, L.; Hedlund, K.O.; Johansson, J.; Chapman, M.R.; Jacobson, S.H.; Romling, U.; Agerberth, B. and Brauner, A. (2010) Uropathogenic escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide ll-37. PLoS Pathog., 6, e1001010.
73. Dean, S.N.; Bishop, B.M. and van Hoek, M.L. (2011) Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against staphylococcus aureus. BMC Microbiol., 11, 114.
74. Sol, A.; Ginesin, O.; Chaushu, S.; Karra, L.; Coppenhagen-Glazer, S.; Ginsburg, I. and Bachrach, G. (2013) Ll-37 opsonizes and inhibits biofilm formation of aggregatibacter actinomycetemcomitans at subbactericidal concentrations. Infect. Immun., 81, 3577-3585.
75. Pompilio, A.; Pomponio, S.; Crocetta, V.; Gherardi, G.; Verginelli, F.; Fiscarelli, E.; Dicuonzo, G.; Savini, V.; D'Antonio, D. and Di Bonaventura, G. (2011) Phenotypic and genotypic characterization of stenotrophomonas maltophilia isolates from patients with cystic fibrosis: Genome diversity, biofilm formation, and virulence. BMC Microbiol., 11, 159.
76. Kanthawong, S.; Bolscher, J.G.; Veerman, E.C.; van Marle, J.; de Soet, H.J.; Nazmi, K.; Wongratanacheewin, S., and Taweechaisupapong, S. (2012) Antimicrobial and antibiofilm activity of ll-37 and its truncated variants against burkholderia pseudomallei. Int. J. Antimicrob. Agents, 39, 39-44.
77. Howell, M.D.; Jones, J.F.; Kisich, K.O.; Streib, J.E.; Gallo, R.L. and Leung, D.Y. (2004) Selective killing of vaccinia virus by ll-37: Implications for eczema vaccinatum. J. Immunol., 172, 1763-1767.
78. Gordon, Y.J.; Huang, L.C.; Romanowski, E.G.; Yates, K.A.; Proske, R.J. and McDermott, A.M. (2005) Human cathelicidin (ll- 37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res., 30, 385-394.
79. Bergman, P.; Walter-Jallow, L.; Broliden, K.; Agerberth, B. and Soderlund, J. (2007) The antimicrobial peptide ll-37 inhibits hiv-1 replication. Curr. HIV Res., 5, 410-415.
80. Howell, M.D.; Wollenberg, A.; Gallo, R.L.; Flaig, M.; Streib, J.E.; Wong, C.; Pavicic, T.; Boguniewicz, M. and Leung, D.Y. (2006) Cathelicidin deficiency predisposes to eczema herpeticum. J. Allergy Clin. Immunol., 117, 836-841.
81. Tripathi, S.; Tecle, T.; Verma, A.; Crouch, E.; White, M. and Hartshorn, K.L. (2013) The human cathelicidin ll-37 inhibits influenza a viruses through a mechanism distinct from that of surfactant protein d or defensins. J. Gen. Virol., 94, 40-49.
82. Crack, L.R.; Jones, L.; Malavige, G.N.; Patel, V. and Ogg, G.S. (2012) Human antimicrobial peptides ll-37 and human betadefensin- 2 reduce viral replication in keratinocytes infected with varicella zoster virus. Clin. Exp. Dermatol., 37, 534-543.
83. Barlow, P.G.; Svoboda, P.; Mackellar, A.; Nash, A.A.; York, I.A.; Pohl, J.; Davidson, D.J. and Donis, R.O. (2011) Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin ll-37. PLoS ONE, 6, e25333.
84. den Hertog, A.L.; van Marle, J.; van Veen, H.A.; Van't Hof, W.; Bolscher, J.G.; Veerman, E.C. and Nieuw Amerongen, A.V. (2005) Candidacidal effects of two antimicrobial peptides: Histatin 5 causes small membrane defects, but ll-37 causes massive disruption of the cell membrane. Biochem. J., 388, 689-695.
85. Rico-Mata, R.; De Leon-Rodriguez, L.M. and Avila, E.E. (2013) Effect of antimicrobial peptides derived from human cathelicidin ll- 37 on entamoeba histolytica trophozoites. Exp. Parasitol., 133, 300-306.
86. Nijnik, A. and Hancock, R.E. (2009) The roles of cathelicidin ll-37 in immune defences and novel clinical applications. Curr. Opin. Hematol., 16, 41-47.
87. Bowdish, D.M.; Davidson, D.J. and Hancock, R.E. (2006) Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol., 306, 27-66.
88. Bucki, R.; Leszczynska, K.; Namiot, A. and Sokolowski, W. (2010) Cathelicidin ll-37: A multitask antimicrobial peptide. Arch. Immunol. Ther. Exp. (Warsz), 58, 15-25.
89. Le, Y.; Oppenheim, J.J. and Wang, J.M. (2001) Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev., 12, 91-105.
90. De, Y.; Chen, Q.; Schmidt, A.P.; Anderson, G.M.; Wang, J.M.; Wooters, J.; Oppenheim, J.J. and Chertov, O. (2000) Ll-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (fprl1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and t cells. J. Exp. Med., 192, 1069-1074.
91. Fu, H.; Karlsson, J.; Bylund, J.; Movitz, C.; Karlsson, A. and Dahlgren, C. (2006) Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leukoc. Biol., 79, 247-256.
92. Coffelt, S.B.; Tomchuck, S.L.; Zwezdaryk, K.J.; Danka, E.S. and Scandurro, A.B. (2009) Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Mol. Cancer Res., 7, 907-915.
93. Kovach, M.A.; Ballinger, M.N.; Newstead, M.W.; Zeng, X.; Bhan, U.; Yu, F.S.; Moore, B.B.; Gallo, R.L. and Standiford, T.J. (2012) Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in gram-negative bacterial pneumonia. J. Immunol., 189, 304-311.
94. Nagaoka, I.; Tamura, H. and Hirata, M. (2006) An antimicrobial cathelicidin peptide, human cap18/ll-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and p2x7. J. Immunol., 176, 3044-3052.
95. Koczulla, R.; von Degenfeld, G.; Kupatt, C.; Krotz, F.; Zahler, S.; Gloe, T.; Issbrucker, K.; Unterberger, P.; Zaiou, M.; Lebherz, C.; Karl, A.; Raake, P.; Pfosser, A.; Boekstegers, P.; Welsch, U.; Hiemstra, P.S.; Vogelmeier, C.; Gallo, R.L.; Clauss, M. and Bals, R. (2003) An angiogenic role for the human peptide antibiotic ll- 37/hcap-18. J. Clin. Invest., 111, 1665-1672.
96. Heilborn, J.D.; Nilsson, M.F.; Kratz, G.; Weber, G.; Sorensen, O.; Borregaard, N. and Stahle-Backdahl, M. (2003) The cathelicidin anti-microbial peptide ll-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest Dermatol., 120, 379-389.
97. Shaykhiev, R.; Beisswenger, C.; Kandler, K.; Senske, J.; Puchner, A.; Damm, T.; Behr, J. and Bals, R. (2005) Human endogenous antibiotic ll-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell Mol. Physiol., 289, L842- L848.
98. Brown, K.L.; Poon, G.F.; Birkenhead, D.; Pena, O.M.; Falsafi, R.; Dahlgren, C.; Karlsson, A.; Bylund, J.; Hancock, R.E. and Johnson, P. (2011) Host defense peptide ll-37 selectively reduces proinflammatory macrophage responses. J. Immunol., 186, 5497- 5505.
99. Ciornei, C.D.; Egesten, A. and Bodelsson, M. (2003) Effects of human cathelicidin antimicrobial peptide ll-37 on lipopolysaccharideinduced nitric oxide release from rat aorta in vitro. Acta Anaesthesiol. Scand., 47, 213-220.
100. Scott, A.; Weldon, S.; Buchanan, P.J.; Schock, B.; Ernst, R.K.; McAuley, D.F.; Tunney, M.M.; Irwin, C.R.; Elborn, J.S. and Taggart, C.C. (2011) Evaluation of the ability of ll-37 to neutralise lps in vitro and ex vivo. PLoS ONE, 6, e26525.
101. Fukumoto, K.; Nagaoka, I.; Yamataka, A.; Kobayashi, H.; Yanai, T.; Kato, Y. and Miyano, T. (2005) Effect of antibacterial cathelicidin peptide cap18/ll-37 on sepsis in neonatal rats. Pediatr. Surg. Int., 21, 20-24.
102. Cirioni, O.; Giacometti, A.; Ghiselli, R.; Bergnach, C.; Orlando, F.; Silvestri, C.; Mocchegiani, F.; Licci, A.; Skerlavaj, B.; Rocchi, M.; Saba, V.; Zanetti, M. and Scalise, G. (2006) Ll-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother., 50, 1672-1679.
103. Ganguly, D.; Chamilos, G.; Lande, R.; Gregorio, J.; Meller, S.; Facchinetti, V.; Homey, B.; Barrat, F.J.; Zal, T. and Gilliet, M. (2009) Self-rna-antimicrobial peptide complexes activate human dendritic cells through tlr7 and tlr8. J. Exp. Med., 206, 1983-1994.
104. Lande, R.; Gregorio, J.; Facchinetti, V.; Chatterjee, B.; Wang, Y.H.; Homey, B.; Cao, W.; Su, B.; Nestle, F.O.; Zal, T.; Mellman, I.; Schroder, J.M.; Liu, Y.J. and Gilliet, M. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449, 564-569.
105. Morizane, S.; Yamasaki, K.; Muhleisen, B.; Kotol, P.F.; Murakami, M.; Aoyama, Y.; Iwatsuki, K.; Hata, T., and Gallo, R.L. (2012) Cathelicidin antimicrobial peptide ll-37 in psoriasis enables keratinocyte reactivity against tlr9 ligands. J. Invest. Dermatol., 132, 135-143.
106. Into, T.; Inomata, M.; Shibata, K. and Murakami, Y. (2010) Effect of the antimicrobial peptide ll-37 on toll-like receptors 2-, 3- and 4- triggered expression of il-6, il-8 and cxcl10 in human gingival fibroblasts. Cell Immunol., 264, 104-109.
107. Filewod, N.C.; Pistolic, J. and Hancock, R.E. (2009) Low concentrations of ll-37 alter il-8 production by keratinocytes and bronchial epithelial cells in response to proinflammatory stimuli. FEMS Immunol. Med. Microbiol., 56, 233-240.
108. Lai, Y.; Yi, G.; Chen, A.; Bhardwaj, K.; Tragesser, B.J.; Rodrigo, A.V.; Zlotnick, A.; Mukhopadhyay, S.; Ranjith-Kumar, C.T., and Kao, C.C. (2011) Viral double-strand rna-binding proteins can enhance innate immune signaling by toll-like receptor 3. PLoS ONE, 6, e25837.
109. Pochet, S.; Tandel, S.; Querriere, S.; Tre-Hardy, M.; Garcia- Marcos, M.; De Lorenzi, M.; Vandenbranden, M.; Marino, A.; Devleeschouwer, M. and Dehaye, J.P. (2006) Modulation by ll-37 of the responses of salivary glands to purinergic agonists. Mol. Pharmacol., 69, 2037-2046.
110. Elssner, A.; Duncan, M.; Gavrilin, M. and Wewers, M.D. (2004) A novel p2x7 receptor activator, the human cathelicidin-derived peptide ll37, induces il-1 beta processing and release. J. Immunol., 172, 4987-4994.
111. Otte, J.M.; Zdebik, A.E.; Brand, S.; Chromik, A.M.; Strauss, S.; Schmitz, F.; Steinstraesser, L. and Schmidt, W.E. (2009) Effects of the cathelicidin ll-37 on intestinal epithelial barrier integrity. Regul. Pept., 156, 104-117.
112. Byfield, F.J.; Wen, Q.; Leszczynska, K.; Kulakowska, A.; Namiot, Z.; Janmey, P.A. and Bucki, R. (2011) Cathelicidin ll-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability. Am. J. Physiol. Cell Physiol., 300, C105-C112.
113. Montreekachon, P.; Chotjumlong, P.; Bolscher, J.G.; Nazmi, K.; Reutrakul, V. and Krisanaprakornkit, S. (2011) Involvement of p2x(7) purinergic receptor and mek1/2 in interleukin-8 upregulation by ll-37 in human gingival fibroblasts. J. Periodontal. Res., 46, 327-337.
114. Chotjumlong, P.; Bolscher, J.G.; Nazmi, K.; Reutrakul, V.; Supanchart, C.; Buranaphatthana, W. and Krisanaprakornkit, S. (2013) Involvement of the p2x7 purinergic receptor and c-jun n-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin e2 induction by ll-37. J. Innate. Immun., 5, 72-83.
115. Zhang, Z.; Cherryholmes, G.; Chang, F.; Rose, D.M.; Schraufstatter, I. and Shively, J.E. (2009) Evidence that cathelicidin peptide ll-37 may act as a functional ligand for cxcr2 on human neutrophils. Eur. J. Immunol., 39, 3181-3194.
116. Subramanian, H.; Gupta, K.; Guo, Q.; Price, R. and Ali, H. (2011) Mas-related gene x2 (mrgx2) is a novel g protein-coupled receptor for the antimicrobial peptide ll-37 in human mast cells: Resistance to receptor phosphorylation, desensitization, and internalization. J. Biol. Chem., 286, 44739-44749.
117. Yin, J. and Yu, F.S. (2010) Ll-37 via egfr transactivation to promote high glucose-attenuated epithelial wound healing in organcultured corneas. Invest. Ophthalmol. Vis. Sci., 51, 1891-1897.
118. Tjabringa, G.S.; Aarbiou, J.; Ninaber, D.K.; Drijfhout, J.W.; Sorensen, O.E.; Borregaard, N.; Rabe, K.F. and Hiemstra, P.S. (2003) The antimicrobial peptide ll-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol., 171, 6690-6696.
119. Tokumaru, S.; Sayama, K.; Shirakata, Y.; Komatsuzawa, H.; Ouhara, K.; Hanakawa, Y.; Yahata, Y.; Dai, X.; Tohyama, M.; Nagai, H.; Yang, L.; Higashiyama, S.; Yoshimura, A.; Sugai, M. and Hashimoto, K. (2005) Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide ll-37. J. Immunol., 175, 4662-4668.
120. Niyonsaba, F.; Nagaoka, I. and Ogawa, H. (2006) Human defensins and cathelicidins in the skin: Beyond direct antimicrobial properties. Crit. Rev. Immunol., 26, 545-576.
121. Braff, M.H.; Hawkins, M.A.; Di Nardo, A.; Lopez-Garcia, B.; Howell, M.D.; Wong, C.; Lin, K.; Streib, J.E.; Dorschner, R.; Leung, D.Y. and Gallo, R.L. (2005) Structure-function relationships among human cathelicidin peptides: Dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol., 174, 4271-4278.
122. Sorensen, O.; Cowland, J.B.; Askaa, J. and Borregaard, N. (1997) An elisa for hcap-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods, 206, 53-59.
123. Agerberth, B.; Buentke, E.; Bergman, P.; Eshaghi, H.; Gabrielsson, S.; Gudmundsson, G.H. and Scheynius, A. (2006) Malassezia sympodialis differently affects the expression of ll-37 in dendritic cells from atopic eczema patients and healthy individuals. Allergy, 61, 422-430.
124. Di Nardo, A.; Vitiello, A. and Gallo, R.L. (2003) Cutting edge: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol., 170, 2274-2278.
125. Agerberth, B.; Charo, J.; Werr, J.; Olsson, B.; Idali, F.; Lindbom, L.; Kiessling, R.; Jornvall, H.; Wigzell, H. and Gudmundsson, G.H. (2000) The human antimicrobial and chemotactic peptides ll-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood, 96, 3086-3093.
126. Lowry, M.B.; Guo, C.; Borregaard, N. and Gombart, A.F. (2014) Regulation of the human cathelicidin antimicrobial peptide gene by 1alpha, 25-dihydroxyvitamin d in primary immune cells. J. Steroid Biochem. Mol. Biol., 143C, 183-191.
127. Aberg, K.M.; Man, M.Q.; Gallo, R.L.; Ganz, T.; Crumrine, D.; Brown, B.E.; Choi, E.H.; Kim, D.K.; Schroder, J.M.; Feingold, K.R. and Elias, P.M. (2008) Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J. Invest. Dermatol., 128, 917-925.
128. Hase, K.; Eckmann, L.; Leopard, J.D.; Varki, N. and Kagnoff, M.F. (2002) Cell differentiation is a key determinant of cathelicidin ll- 37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect. Immun., 70, 953-963.
129. Bals, R.; Wang, X.; Zasloff, M. and Wilson, J.M. (1998) The peptide antibiotic ll-37/hcap-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA, 95, 9541-9546.
130. Frohm Nilsson, M.; Sandstedt, B.; Sorensen, O.; Weber, G.; Borregaard, N. and Stahle-Backdahl, M. (1999) The human cationic antimicrobial protein (hcap18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun., 67, 2561-2566.
131. Gombart, A.F. (2009) The vitamin d-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol., 4, 1151-1165.
132. Dorschner, R.A.; Pestonjamasp, V.K.; Tamakuwala, S.; Ohtake, T.; Rudisill, J.; Nizet, V.; Agerberth, B.; Gudmundsson, G.H. and Gallo, R.L. (2001) Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group a streptococcus. J. Invest. Dermatol., 117, 91-97.
133. Sorensen, O.E.; Cowland, J.B.; Theilgaard-Monch, K.; Liu, L.; Ganz, T. and Borregaard, N. (2003) Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol., 170, 5583- 5589.
134. Aberg, K.M.; Radek, K.A.; Choi, E.H.; Kim, D.K.; Demerjian, M.; Hupe, M.; Kerbleski, J.; Gallo, R.L.; Ganz, T.; Mauro, T.; Feingold, K.R. and Elias, P.M. (2007) Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J. Clin. Invest., 117, 3339-3349.
135. Krutzik, S.R.; Hewison, M.; Liu, P.T.; Robles, J.A.; Stenger, S.; Adams, J.S. and Modlin, R.L. (2008) Il-15 links tlr2/1-induced macrophage differentiation to the vitamin d-dependent antimicrobial pathway. J. Immunol., 181, 7115-7120.
136. Campbell, Y.; Fantacone, M.L. and Gombart, A.F. (2012) Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism. Eur. J. Nutr., 51, 899-907.
137. Hansdottir, S.; Monick, M.M.; Hinde, S.L.; Lovan, N.; Look, D.C. and Hunninghake, G.W. (2008) Respiratory epithelial cells convert inactive vitamin d to its active form: Potential effects on host defense. J. Immunol., 181, 7090-7099.
138. Schauber, J.; Dorschner, R.A.; Coda, A.B.; Buchau, A.S.; Liu, P.T.; Kiken, D.; Helfrich, Y.R.; Kang, S.; Elalieh, H.Z.; Steinmeyer, A.; Zugel, U.; Bikle, D.D.; Modlin, R.L. and Gallo, R.L. (2007) Injury enhances tlr2 function and antimicrobial peptide expression through a vitamin d-dependent mechanism. J. Clin. Invest., 117, 803-811.
139. Edfeldt, K.; Liu, P.T.; Chun, R.; Fabri, M.; Schenk, M.; Wheelwright, M.; Keegan, C.; Krutzik, S.R.; Adams, J.S.; Hewison, M. and Modlin, R.L. (2010) T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin d metabolism. Proc. Natl. Acad. Sci. USA, 107, 22593-22598.
140. Schrumpf, J.A.; van Sterkenburg, M.A.; Verhoosel, R.M.; Zuyderduyn, S., and Hiemstra, P.S. (2012) Interleukin 13 exposure enhances vitamin d-mediated expression of the human cathelicidin antimicrobial peptide 18/ll-37 in bronchial epithelial cells. Infect. Immun., 80, 4485-4494.
141. Bacchetta, J.; Sea, J.L.; Chun, R.F.; Lisse, T.S.; Wesseling-Perry, K.; Gales, B.; Adams, J.S.; Salusky, I.B., and Hewison, M. (2013) Fibroblast growth factor 23 inhibits extrarenal synthesis of 1, 25- dihydroxyvitamin d in human monocytes. J. Bone Miner. Res., 28, 46-55.
142. Amano, Y.; Cho, Y.; Matsunawa, M.; Komiyama, K. and Makishima, M. (2009) Increased nuclear expression and transactivation of vitamin d receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J. Steroid. Biochem. Mol. Biol., 114, 144-151.
143. Chuma, M.; Endo-Umeda, K.; Shimba, S.; Yamada, S., and Makishima, M. (2012) Hairless modulates ligand-dependent activation of the vitamin d receptor-retinoid x receptor heterodimer. Biol. Pharm. Bull, 35, 582-587.
144. Barna, B.P.; Culver, D.A.; Kanchwala, A.; Singh, R.J.; Huizar, I.; Abraham, S.; Malur, A.; Marshall, I.; Kavuru, M.S. and Thomassen, M.J. (2012) Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J. Innate Immun., 4, 569-578.
145. Gombart, A.; Saito, T. and Koeffler, H.P. (2009) Exapation of an ancient alu short interspersed element provides a highly conserved vitamin d-mediated innate immune response in humans and primates. BMC Genomics, 10, 321.
146. Gombart, A.F.; Bhan, I.; Borregaard, N.; Tamez, H.; Camargo, C.A., Jr.; Koeffler, H.P. and Thadhani, R. (2009) Low plasma level of cathelicidin antimicrobial peptide (hcap18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin. Infect. Dis., 48, 418-424.
147. Jeng, L.; Yamshchikov, A.V.; Judd, S.E.; Blumberg, H.M.; Martin, G.S.; Ziegler, T.R. and Tangpricha, V. (2009) Alterations in vitamin d status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J. Transl. Med., 7, 28.
148. Bhan, I.; Camargo, C.A., Jr.; Wenger, J.; Ricciardi, C.; Ye, J.; Borregaard, N. and Thadhani, R. (2011) Circulating levels of 25- hydroxyvitamin d and human cathelicidin in healthy adults. J. Allergy Clin. Immunol., 127(5), 1302-1304.e1
149. Dixon, B.M.; Barker, T.; McKinnon, T.; Cuomo, J.; Frei, B.; Borregaard, N. and Gombart, A.F. (2012) Positive correlation between circulating cathelicidin antimicrobial peptide (hcap18/ll- 37) and 25-hydroxyvitamin d levels in healthy adults. BMC Res. Notes, 5, 575.
150. Alvarez-Rodriguez, L.; Lopez-Hoyos, M.; Garcia-Unzueta, M.; Amado, J.A.; Cacho, P.M. and Martinez-Taboada, V.M. (2012) Age and low levels of circulating vitamin d are associated with impaired innate immune function. J. Leukoc. Biol., 91, 829-838.
151. Kanda, N.; Hau, C.S.; Tada, Y.; Sato, S. and Watanabe, S. (2012) Decreased serum ll-37 and vitamin d3 levels in atopic dermatitis: Relationship between il-31 and oncostatin m. Allergy, 67, 804-812.
152. Mandic Havelka, A.; Yektaei-Karin, E.; Hultenby, K.; Sorensen, O.E.; Lundahl, J.; Berggren, V. and Marchini, G. (2010) Maternal plasma level of antimicrobial peptide ll37 is a major determinant factor of neonatal plasma ll37 level. Acta Paediatr., 99, 836-841.
153. Leow, L.; Simpson, T.; Cursons, R.; Karalus, N. and Hancox, R.J. (2011) Vitamin d, innate immunity and outcomes in community acquired pneumonia. Respirology, 16, 611-616.
154. Hata, T.R.; Kotol, P.; Jackson, M.; Nguyen, M.; Paik, A.; Udall, D.; Kanada, K.; Yamasaki, K.; Alexandrescu, D. and Gallo, R.L. (2008) Administration of oral vitamin d induces cathelicidin production in atopic individuals. J. Allergy Clin. Immunol., 122, 829-831.
155. Hata, T.R.; Audish, D.; Kotol, P.; Coda, A.; Kabigting, F.; Miller, J.; Alexandrescu, D.; Boguniewicz, M.; Taylor, P.; Aertker, L.; Kesler, K.; Hanifin, J.M.; Leung, D.Y. and Gallo, R.L. (2014) A randomized controlled double-blind investigation of the effects of vitamin d dietary supplementation in subjects with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol., 28, 781-789
156. Adams, J.S.; Ren, S.; Liu, P.T.; Chun, R.F.; Lagishetty, V.; Gombart, A.F.; Borregaard, N.; Modlin, R.L. and Hewison, M. (2009) Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol., 182, 4289-4295.
157. Alvarez, J.A.; Zughaier, S.M.; Law, J.; Hao, L.; Wasse, H.; Ziegler, T.R. and Tangpricha, V. (2013) Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur. J. Clin. Nutr., 67, 264-269.
158. Das, M.; Tomar, N.; Sreenivas, V.; Gupta, N. and Goswami, R. (2014) Effect of vitamin d supplementation on cathelicidin, ifngamma, il-4 and th1/th2 transcription factors in young healthy females. Eur. J. Clin. Nutr., 68, 338-343.
159. Vahavihu, K.; Ala-Houhala, M.; Peric, M.; Karisola, P.; Kautiainen, H.; Hasan, T.; Snellman, E.; Alenius, H.; Schauber, J., and Reunala, T. (2010) Narrowband ultraviolet b treatment improves vitamin d balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br. J. Dermatol., 163, 321-328.
160. Al-Mutairi, N. and Shaaban, D. (2014) Effect of narrowband ultraviolet b therapy on serum vitamin d and cathelicidin (ll-37) in patients with chronic plaque psoriasis. J. Cutan. Med. Surg., 18, 43-48.
161. Ala-Houhala, M.J.; Vahavihu, K.; Hasan, T.; Kautiainen, H.; Ylianttila, L.; Viljakainen, H.T.; Snellman, E., and Reunala, T. (2012) Comparison of narrowband ultraviolet b exposure and oral vitamin d substitution on serum 25-hydroxyvitamin d concentration. Br. J. Dermatol., 167, 160-164.
162. Hertting, O.; Holm, A.; Luthje, P.; Brauner, H.; Dyrdak, R.; Jonasson, A.F.; Wiklund, P.; Chromek, M. and Brauner, A. (2010) Vitamin d induction of the human antimicrobial peptide cathelicidin in the urinary bladder. PLoS One, 5, e15580.